Diagnostics: Page 2
-
Icahn says his Illumina board candidates will ‘ask the tough questions’
The billionaire investor repeated his call for the ouster of CEO Francis deSouza in a new letter to fellow shareholders.
By Susan Kelly • May 5, 2023 -
Algorithm may help avoid 40% of kidney transplant rejection misdiagnoses: study
The decision-support system “could have important clinical implications for the management and treatment of transplant recipients,” researchers found.
By Nick Paul Taylor • May 5, 2023 -
BD raises full-year forecasts again, expects Alaris infusion pump approval
The company said revenue increases in a number of its product lines were faster than market growth rates, suggesting it’s gaining share.
By Susan Kelly • May 4, 2023 -
Hologic, after overcoming chip shortage, starts considering larger M&A deals
The breast health unit “emphatically returned to growth” because of improvements to the supply of semiconductors.
By Nick Paul Taylor • May 2, 2023 -
Great Britain proposes allowing CE marks until 2030 to minimize Brexit disruption
The extended timeline to create a new regulatory system in England, Scotland and Wales is intended to prevent medical device shortages.
By Nick Paul Taylor • May 1, 2023 -
Illumina gets cybersecurity warning from FDA over sequencing software
The vulnerability could result in an attacker gaining control of an instrument remotely and altering genomic data results, the agency said.
By Susan Kelly • Updated April 28, 2023 -
Quest Diagnostics to pay $450M to buy liquid biopsy cancer test developer as Q1 revenue drops
The laboratory services provider said patients are returning to the healthcare system for routine care, but COVID testing has plummeted as the pandemic winds down.
By Susan Kelly • April 27, 2023 -
Thermo Fisher reports 9% drop in Q1 revenue, shares slip
The drop in revenue accompanied a 41% decline in net income, with Life Sciences Solutions and Specialty Diagnostics revenue declining by double digits.
By Peter Green • April 26, 2023 -
Illumina, under pressure from Icahn, outlines plan to reduce more expenses
The company outlined in its first-quarter earnings call a second set of cost cuts aimed at accelerating margin improvement.
By Nick Paul Taylor • April 26, 2023 -
GE HealthCare revenue up in first quarter as a standalone company, but shares drop
Steady demand and supply chain improvements have helped it grow the business, even as inflation and foreign exchange rates pressure its income.
By Elise Reuter • Updated April 25, 2023 -
Labcorp posts Q1 net decline, says Fortrea spinoff on track for mid-year
The company’s first quarter results in its base operations were boosted by a partnership to manage hospital laboratories for Ascension.
By Susan Kelly • April 25, 2023 -
Opinion
Ending free COVID tests risks worsening the pandemic
If Americans start paying out of pocket for COVID tests, they'll test much less — if at all, argue representatives of the Testing at Home Coalition.
By Amy Kelbick and Eric Zimmerman • April 20, 2023 -
Illumina slaps back at Icahn’s board nominees, opens proxy collection
The fight continues as Illumina aims to block Icahn’s nominees from ousting its CEO and board chair.
By Peter Green • April 20, 2023 -
Abbott hit with FDA warning letter over unapproved changes to heart disease test
The FDA said that four changes made to the tests “could significantly affect the safety or effectiveness of the devices.”
By Nick Paul Taylor • Updated April 20, 2023 -
Abbott boosts organic sales outlook as device demand accelerates
A rebound in surgical procedure volumes as hospital staffing improved at the start of the year partially offset a steep drop in COVID-19 testing sales.
By Susan Kelly • April 19, 2023 -
Genomics companies Ultima, Genome Insight partner to offer low-cost sequencing
Genome Insight will develop whole genome bioinformatics for Ultima’s sequencing instrument platform under the agreement.
By Susan Kelly • April 14, 2023 -
Illumina-Icahn proxy battle heats up as Grail divestment orders loom
DNA-sequencing provider Illumina is headed for a showdown with billionaire financier Carl Icahn over three of nine seats on its board of directors as it continues to defy regulators’ orders to divest cancer test maker Grail.
By Susan Kelly • April 12, 2023 -
Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment
The startup says its genomics platform can improve on conventional sequencing by uncovering drug target vulnerabilities directly in patient tumor samples.
By Nick Paul Taylor • April 12, 2023 -
Icahn pushes for spinoff of Illumina’s Grail liquid biopsy unit
The billionaire financier, who is waging a proxy fight for seats on Illumina’s board, is arguing that Grail should become a standalone publicly traded company.
By Susan Kelly • April 11, 2023 -
Medtech buyouts by private equity in Q4 shed light on deal-making trends in 2023: report
Medtech companies are continuing to spin off assets to realign portfolios, creating opportunities for private equity firms to buy businesses and exit existing investments.
By Nick Paul Taylor • April 11, 2023 -
Illumina backs its board in proxy fight with Icahn
Illumina directors up for re-election to one-year terms include prominent leaders in healthcare such as former FDA Commissioner Scott Gottlieb and longtime Intuitive Surgical CEO Gary Guthart.
By Susan Kelly • April 10, 2023 -
Q&A
Friday Q&A: Fujifilm’s Henry Izawa on navigating a tough hospital equipment market
The CEO of Fujifilm Healthcare Americas discusses integrating Hitachi’s diagnostic imaging business, new product launches and how hospital budgets are changing the market for imaging.
By Elise Reuter • April 7, 2023 -
Icahn ramps up rhetoric on Illumina after FTC orders Grail sale
In a letter to Illumina shareholders, Icahn says the two companies “should be separated immediately” to protect “long term growth prospects.”
By Peter Green • April 5, 2023 -
Diagnostics execs charged with concealing lead test flaw
The former CEO and two other top executives of Magellan Diagnostics are accused of hiding a malfunction that caused tens of thousands of children and adults to receive inaccurately low lead test results.
By Susan Kelly • Updated April 5, 2023 -
Diagnostic testing reform bill has a path to the finish line this year: AdvaMed
Legislators recently reintroduced the VALID Act, which would bring lab-developed tests and in-vitro diagnostics under one framework, after failing to pass the bill twice last year.
By Elise Reuter • Updated April 5, 2023